rss
J Clin Pathol 2007;60:633-641 doi:10.1136/jcp.2006.039107
  • Original article

Expression of nuclear insulin receptor substrate 1 in breast cancer

  1. Diego Sisci1,*,
  2. Catia Morelli1,*,
  3. Cecilia Garofalo1,
  4. Francesco Romeo2,
  5. Lucio Morabito2,
  6. Filomena Casaburi2,
  7. Emilia Middea1,
  8. Sandra Cascio3,
  9. Elvira Brunelli4,
  10. Sebastiano Andò5,
  11. Eva Surmacz3
  1. 1Department of Pharmaco-Biology, University of Calabria, Arcavacata di Rende, Italy
  2. 2Division of Anatomo-Pathology, Annunziata Hospital, Cosenza, Italy
  3. 3Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, Pennsylvania, USA
  4. 4Department of Ecology, University of Calabria, Arcavacata di Rende, Italy
  5. 5Department of Cellular Biology, University of Calabria, Arcavacata di Rende, Italy
  1. Correspondence to:
 Dr E Surmacz
 Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, 1900 N 12th St Rm 446, Philadelphia, PA 19122, USA; surmacz{at}temple.edu
  • Accepted 13 June 2006
  • Published Online First 1 August 2006

Abstract

Background: Insulin receptor substrate 1 (IRS-1), a cytoplasmic protein transmitting signals from the insulin and insulin-like growth factor 1 receptors, has been implicated in breast cancer. Previously, it was reported that IRS-1 can be translocated to the nucleus and modulate oestrogen receptor α (ERα) activity in vitro. However, the expression of nuclear IRS-1 in breast cancer biopsy specimens has never been examined.

Aims: To assess whether nuclear IRS-1 is present in breast cancer and non-cancer mammary epithelium, and whether it correlates with other markers, especially ERα. Parallel studies were carried out for the expression of cytoplasmatic IRS-1.

Methods: IRS-1 and ERα expression was assessed by immunohistochemical analysis. Data were evaluated using Pearson’s correlation, linear regression and receiver operating characteristic analysis.

Results: Median nuclear IRS-1 expression was found to be low in normal mammary epithelial cells (1.6%) and high in benign tumours (20.5%), ductal grade 2 carcinoma (11.0%) and lobular carcinoma (~30%). Median ERα expression in normal epithelium, benign tumours, ductal cancer grade 2 and 3, and lobular cancer grade 2 and 3 were 10.5, 20.5, 65.0, 0.0, 80 and 15%, respectively. Nuclear IRS-1 and ERα positively correlated in ductal cancer (p<0.001) and benign tumours (p<0.01), but were not associated in lobular cancer and normal mammary epithelium. In ductal carcinoma, both nuclear IRS-1 and ERα negatively correlated with tumour grade, size, mitotic index and lymph node involvement. Cytoplasmic IRS-1 was expressed in all specimens and positively correlated with ERα in ductal cancer.

Conclusions: A positive association between nuclear IRS-1 and ERα is a characteristic for ductal breast cancer and marks a more differentiated, non-metastatic phenotype.

Footnotes

  • ↵* These authors contributed equally to this work.

  • Published Online First 1 August 2006

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. jcp.2006.039107v1
    2. jcp.2006.039107v2
    3. 60/6/633 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content


Free trial
Individuals may register for a free 60 day online trial to all content.

Free archive
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they ar